Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver D Howes

Showing results (61-70 of 329) with videos related to

Pageof 33
Sort By:
Biological Psychiatry|October 11, 2016
The Role of Genes, Stress, and Dopamine in the Development of SchizophreniaOliver D Howes, Robert McCutcheon, Michael J Owen, et al.
The American Journal of Psychiatry|June 1, 2024
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?Luke J Vano, Mattia Veronese, Robert A McCutcheon, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|September 19, 2019
Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studiesStephen J Kaar, Ilinca Angelescu, Tiago Reis Marques, et al.
Molecular Psychiatry|March 8, 2018
Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measuresEmanuele Felice Osimo, Katherine Beck, Tiago Reis Marques, et al.
Journal of Clinical Psychopharmacology|October 23, 2024
Aripiprazole-Associated QT Prolongation in a Healthy Study Volunteer: A Case Report and Literature ReviewGeorge E Chapman, Martin Osugo, Antonio de Marvao, et al.
International Journal of Molecular Sciences|December 24, 2021
Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical StudiesNina Dedic, Heather Dworak, Courtney Zeni, et al.
Trends in Neurosciences|November 11, 2022
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disordersEls F Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Acta Psychiatrica Scandinavica|March 9, 2022
Low COVID-19 vaccination rates in people with severe mental illness and reasons for this: An out-patient studyAtheeshaan Arumuham, Oisin O'Brien, Zain Ahmad, et al.
JAMA Psychiatry|March 16, 2017
Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysisAbhishekh H Ashok, Yuya Mizuno, Nora D Volkow, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 15, 2025
The hypothesis of biologically based subtypes of schizophrenia: a 10-year updateOliver D Howes, Bernard R Bukala, Sameer Jauhar, et al.
Pageof 33

Showing results (61-70 of 329) with videos related to

Sort By:
Pageof 33
Biological Psychiatry|October 11, 2016
The Role of Genes, Stress, and Dopamine in the Development of SchizophreniaOliver D Howes, Robert McCutcheon, Michael J Owen, et al.
The American Journal of Psychiatry|June 1, 2024
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?Luke J Vano, Mattia Veronese, Robert A McCutcheon, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|September 19, 2019
Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studiesStephen J Kaar, Ilinca Angelescu, Tiago Reis Marques, et al.
Molecular Psychiatry|March 8, 2018
Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measuresEmanuele Felice Osimo, Katherine Beck, Tiago Reis Marques, et al.
Journal of Clinical Psychopharmacology|October 23, 2024
Aripiprazole-Associated QT Prolongation in a Healthy Study Volunteer: A Case Report and Literature ReviewGeorge E Chapman, Martin Osugo, Antonio de Marvao, et al.
International Journal of Molecular Sciences|December 24, 2021
Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical StudiesNina Dedic, Heather Dworak, Courtney Zeni, et al.
Trends in Neurosciences|November 11, 2022
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disordersEls F Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Acta Psychiatrica Scandinavica|March 9, 2022
Low COVID-19 vaccination rates in people with severe mental illness and reasons for this: An out-patient studyAtheeshaan Arumuham, Oisin O'Brien, Zain Ahmad, et al.
JAMA Psychiatry|March 16, 2017
Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysisAbhishekh H Ashok, Yuya Mizuno, Nora D Volkow, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|January 15, 2025
The hypothesis of biologically based subtypes of schizophrenia: a 10-year updateOliver D Howes, Bernard R Bukala, Sameer Jauhar, et al.
Pageof 33